Aspirin in tuberculous meningitis
- PMID: 34027331
- PMCID: PMC8129888
- DOI: 10.1016/j.eclinm.2021.100871
Aspirin in tuberculous meningitis
Conflict of interest statement
The authors are funded in part by Wellcome [104803, 211159, 230135]. For the purpose of Open Access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The authors are also supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC0010218), the UK Medical Research Council (FC00101218), and Wellcome (FC00101218). The authors also receive support from EDCTP (RIA2017T-2019 109237), NIH (R01AI145436) and Meningitis Now. The authors declare no conflict of interests.
References
-
- Selvaraj J.U. Identification of predictors of cerebrovascular infarcts in patients with tuberculous meningitis. Int J Mycobacteriol. 2020;9(3):303–308. - PubMed
-
- Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–235. - PubMed
-
- Richman I.B., Owens D.K. Aspirin for primary prevention. Med Clin North Am. 2017;101(4):713–724. - PubMed
-
- Schoeman J. Coagulant and fibrinolytic status in tuberculous meningitis. Pediatr Infect Dis J. 2007;26(5):428–431. - PubMed
-
- Botting R.M. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep. 2010;62(3):518–525. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
